Three Jones Day partners listed among California's 2019 Top Intellectual Property Lawyers by the Daily Journal
Three Jones Day partners have been named to the Daily Journal's 2019 list of "Top Intellectual Property Lawyers in California." The list was compiled from hundreds of nominations submitted by lawyers statewide, with the honorees selected by editors based on the impact of their work in intellectual property.
The Jones Day partners recognized are:
- Anthony M. Insogna, chair of Jones Day's global Intellectual Property Practice and partner in the San Diego Office, has more than 28 years of patent law experience assisting emerging companies with protecting their breakthrough technologies to enforcing and defending patents for international pharmaceutical and biotech companies worldwide. Widely recognized as a life sciences industry leader, he has successfully protected biotech and pharmaceutical products alike. Most recently, Celgene, one of the world’s leading hematology and oncology companies that Anthony has represented since 1996, is in the process of being acquired by Bristol-Myers Squibb for approximately $74 billion. Mr. Insogna was recognized by the Daily Journal for several matters, including the successful defense of inter partes reviews (IPRs) for AbbVie and Celgene, and successful IPRs for petitioner Merck & Co. This is the fifth consecutive year Mr. Insogna has been named to this list.
- Randy Kay, San Diego, has more than 25 years of experience in the courtroom handling trade secret, patent, trademark, copyright, unfair competition, and business disputes. Randy represents plaintiff and defendant clients including technology, telecom, semiconductor, biotech, and medical device companies. The Daily Journal recognized Mr. Kay for his work representing Qualcomm Incorporated and Micron Technology in trade secret litigation. This is Mr. Kay’s fifth appearance on the "Top Intellectual Property Lawyers in California" list.
- Tamera M. Weisser Ph.D., San Diego, is co-chair of Jones Day’s global Patent Prosecution group and has 20 years of experience in biologics global patent portfolio development and enforcement, and successfully defended innovator company patents against biosimilar company challenges in multiple inter partes review proceedings before the USPTO's Patent and Trial Appeal Board. This is the second consecutive year Dr. Weisser has been named to this list.